Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Barricade Therapeutics›
Analysis
AddedMay 6, 2026
UpdatedMay 30, 2026
Barricade Therapeutics

Barricade Therapeutics

Clinical-stage oncology company developing first-in-class oral therapies for genetically driven cancers

HQ
Fort Worth, TX, US
Founded
2017
Accelerator
Texas Medical Center Innovation logoTexas Medical Center InnovationACT 2025
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  5. 05Competitive Risks
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  5. 05Competitive Risks

Memo

Bull case: Non-dilutive grant runway plus UT Southwestern IP de-risk early development; APC-mutant CRC is a large biomarker-defined indication with clear regulatory path; TASIN platform provides optionality across multiple oncology and non-oncology indications.

Bear case: Founder-CEO concentration (Neil Thapar holds Co-Founder plus Board Chair plus CEO plus CSO simultaneously — governance flag); zero institutional biotech VC on cap table in 9 years post-founding suggests prior fundraising friction; reliance on Reg CF crowdfunding in 2026 reinforces this concern. Operationally lean (3 employees) means clinical execution risk is concentrated.

Product Overview

Barricade Therapeutics is a clinical-stage oncology company developing BT-1501, a once-daily oral small-molecule inhibitor of Emopamil Binding Protein (EBP) for advanced colorectal cancer driven by APC mutations (present in approximately 80% of CRC tumors).

Rather than directly targeting Wnt/beta-catenin signaling, BT-1501 exploits synthetic lethality by disrupting sterol-processing pathways APC-mutant cells depend upon, triggering apoptosis selectively in cancer cells. The asset is licensed from UT Southwestern's TASIN platform; preclinical data show 63-74% tumor growth inhibition in advanced CRC animal models. IND filing targeted Q2 2025 with Phase 1 initiation H2 2026.

Market Outlook

Global colorectal cancer therapeutic market is approximately $13B today, projected to reach $20B by 2030 per company materials. APC mutations are present in approximately 80% of CRC patients, defining a large biomarker-selected addressable population.

Current standard of care for advanced CRC (chemotherapy combinations, anti-EGFR/anti-VEGF antibodies, KRAS-G12C inhibitors for the small mutated subset) leaves significant unmet need for the APC-mutant majority. A successful first-in-class oral targeted therapy could capture substantial share if Phase 1 efficacy translates.

Competitive Advantages

Strong non-dilutive funding base: $17M total in CPRIT grants ($3M Seed plus $14M Texas Therapeutics Company Award) with positive Pre-IND FDA feedback already received, enabling Barricade to advance toward first-in-human studies without burning early equity.

Genetically targeted indication (APC-mutant CRC, 80% of CRC patients) carries clear biomarker-defined patient selection — a regulatory and commercial advantage versus broad-spectrum CRC therapies. TASIN platform exclusivity from UT Southwestern provides defensible IP and a multi-asset pipeline runway (neuroblastoma, lymphoma, MS, FAP).

Competitive Disadvantages

Tiny team (3 employees per aVenture 2026-05 snapshot) and pre-clinical asset means Barricade is years from commercial validation. The company has raised only approximately $5.9M in equity and is now running a $1.24M Reg CF StartEngine crowdfunding round in 2026 — a financing path typically used by companies unable to secure traditional Series A from biotech VCs.

IND timeline has slipped: Nov 2024 press release implied near-term IND, but invest-site (April 2026) now positions Phase 1 start in H2 2026. Single-asset clinical-stage risk concentration with no diversifying near-term programs.